Latest treatment of multiple sclerosis Stories
Toronto Stock Exchange Symbol: MS EDMONTON, Feb. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr.
Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb.
Toronto Stock Exchange Symbol: MS EDMONTON, Dec.
Lund, Sweden, November 6, 2008 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at the New York Palace Hotel in New York City, US.
CAMBRIDGE, Mass., Oct. 28 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced today that President & CEO Thomas P.
Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*.
Opexa Therapeutics, a biopharmaceutical company, has announced additional positive data from the company's Phase IIb clinical trial for the treatment of multiple sclerosis.
A drug developed for patients with leukemia also appears to regenerate brain cells and reverse the effects of relapsing-remitting multiple sclerosis, British researchers said on Wednesday.
Opexa Therapeutics, Inc.
By Rita Rubin A leukemia drug was about 70% more effective than a standard therapy in treating early multiple sclerosis, according to clinical trial results in today's New England Journal of Medicine.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).